PMGC Holdings ELAB
NASDAQ ELAB
$6.66 +0.56 (+9.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

PMGC Holdings (ELAB) Other Accumulated Expenses (2022 - 2026)

PMGC Holdings (ELAB) posted Other Accumulated Expenses of $1.3 million for Q1 2026, up 95.8% sequentially from $642925.0 in Q4 2025, and up 551.11% YoY from $193337.0 in Q1 2025.

PMGC Holdings (ELAB) Other Accumulated Expenses (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Other Accumulated Expenses for 5 years, with the latest figure at $1.3 million in Q1 2026.

  • Quarterly Other Accumulated Expenses rose 551.11% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 551.11% YoY) and the FY2025 annual result came in at $642925.0, up 53.36% from the prior year.
  • Other Accumulated Expenses climbed to $1.3 million in Q1 2026 per ELAB's latest filing, from $642925.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $222.7 million in Q3 2023 and troughed at $53355.0 in Q2 2025.
  • A 5-year average of $18.8 million and a median of $210543.0 in 2024 frame the typical range for Other Accumulated Expenses.
  • The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses tumbled 99.96% in 2024, then soared 551.11% in 2026.
  • Over 5 years, Other Accumulated Expenses stood at $154325.0 in 2022, then sank by 50.02% to $77127.0 in 2023, then surged by 443.54% to $419217.0 in 2024, then jumped by 53.36% to $642925.0 in 2025, then soared by 95.8% to $1.3 million in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.3 million, $642925.0, and $315097.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 PMGC Holdings 31.22 Mn 12.43 Mn 385,691.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1.26 Mn
Dec 31, 2025 642,925.00
Sep 30, 2025 315,097.00
Jun 30, 2025 53,355.00
Mar 31, 2025 193,337.00
Dec 31, 2024 419,217.00
Sep 30, 2024 80,368.00
Jun 30, 2024 56,127.00
Mar 31, 2024 227,749.00
Dec 31, 2023 77,127.00
Sep 30, 2023 222.68 Mn
Dec 31, 2022 154,325.00